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Copyright © 2011 JCBN 2011 This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unre- stricted use, distribution, and reproduction in any medium, pro- vided the original work is properly cited. Liver ischemia and reperfusion induced injury is a major clinical
complication associated with hemorrhagic or endotoxin shock
and thermal injury as well as liver transplantation and resectional
surgery. Data obtained from several different studies suggest that
an important initiating event in the pathophysiology of ischemia
and reperfusion induced tissue injury is enhanced production of
superoxide concomitant with a decrease in the bioavailability of
endothelial cell derived nitric oxide. This review will summarize
the evidence supporting the hypothesis that the redox imbalance
induced by alterations in superoxide and nitric oxide generation
creates a more oxidative environment within the different cells
of the liver that enhances the nuclear transcription factor κB 
dependent expression of a variety of different cytokines and
mediators that may promote as well as limit ischemia and
reperfusion induced hepatocellular injury. In addition, the evidence
implicating endothelial cell nitric oxide synthase dependent and
 independent generation of nitric oxide as important regulatory
pathways that act to limit ischemia and reperfusion induced liver
injury and inflammation is also presented.
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Introduction Liver ischemia and reperfusion (I/R)-induced injury is a major
complication associated with hemorrhagic or endotoxin shock
and thermal injury as well as liver transplantation and resectional
surgery. The vast majority of studies performed in experimental
animals have used in situ models of liver I/R suggesting that
data obtained from these investigations are most relevant to
pathophysiological situations or surgical manipulations involving
“warm” (37°C) I/R such as hemorrhagic or endotoxin shock or
resectional surgery. Indeed, the pathophysiological mechanisms
responsible for warm I/R-induced liver injury may be significantly
different than those that occur with the cold ischemia (4°C)
associated with liver storage prior to transplantation.(1,2) Neverthe-
less, a great deal of mechanistic information has been derived
from in situ I/R studies.(3) These studies demonstrate that reperfu-
sion of ischemic tissue initiates a cascade of molecular and cellular
events that culminate in the superoxide anion radical (O2￿−) depen-
dent, nuclear transcription factor-κB (NF-κB)-mediated expres-
sion of both injurious and protective mediators in favor of the
former (Fig. 1).
Post-ischemic liver injury is biphasic in nature consisting of an
acute or early phase and a subacute or late phase.(4,5) The early
phase of injury occurs in the absence of leukocyte infiltration and
is thought to be initiated by a rapid alteration in the redox state of
the tissue in favor of a more oxidative environment. The late phase
of injury is dependent upon the production of several different
cytokines and chemokines that promote the infiltration of large
numbers polymorphonuclear neutrophils (PMNs) and lymphocytes
into the liver interstitium via the up-regulation of endothelial cell
adhesion molecules and formation of chemotactic gradients.(6,7)
Interstitial PMNs become fully activated and release copius
amounts of reactive oxygen species (ROS) together with extra-
cellular matrix degrading enzymes such as collagenase and matrix
metalloproteases.(7) The net result of this inflammatory infiltrate
is an amplification of the acute injurious response resulting in
extensive inflammatory tissue injury.
Over the past 10 years, an emerging body of experimental data
suggest that endothelial cell nitric oxide synthase (eNOS)-derived
NO may limit ROS- and PMN-mediated tissue injury thereby
regulating the subsequent inflammatory response in vivo. Indeed,
it is becoming clear that reperfusion of ischemic tissue induces a
rapid reduction in the bio-availability of NO which is thought to
represent an important initiating event in the pathophysiology of
post-ischemic injury in a variety of different tissues including the
liver, heart, kidney and gut.(8–10) This chapter presents evidence
supporting the hypothesis that: a) I/R enhances the generation
of the O2￿− and b) the I/R-induced decrease in the bioavailability
of NO is mediated directly or indireclty by the O2￿−-dependent
decomposition of endogenous NO. In addition to reducing the
steady state levels of this protective nitrogen oxide, post-ischemic
overproduction of O2￿− as well as other ROS would also alter the
redox potential of the liver creating a more oxidative environment
within the major cell types of liver including the hepatocytes,
Kupffer cells (KCs) and sinusoidal endothelial cells (SECs;
Fig. 1). Increasing the redox potential within these cells would
activate NF-κB thereby promoting the expression of pro-
inflammatory cytokines (e.g., TNF-α, IL-12, IL-1β) that may
injure the tissue directly in the acute phase as well as induce
chemokine and endothelial cell adhesion molecule expression in
the later subacute phase. Activation of this transcription factor
would also induce the expression of certain protective and anti-
apopototic genes that could limit tissue injury following I/R.
The evidence implicating endogenous eNOS-dependent and-
independent generation of NO as important regulatory pathways
that limit the early and late phases of I/R-induced liver injury are
also presented in this review.
Ischemia and Reperfusion Increases Reactive Oxygen
Production, Decreases Nitric Oxide Bioavailability and
Alters the Redox State of the Liver: A recipe for disaster
The early phase of hepatocellular I/R occurs within 1–6 h
following reperfusion and is associated with Kupffer cell (KC)
and possibly lymphocyte activation.(4–6,11) Data obtained from
several different laboratories demonstrate that this acute, PMN-
independent injury may be initiated by alterations in the redox
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state of the post-ischemic liver such that the redox potential
becomes more positive thereby creating a more oxidative environ-
ment. Exactly how this happens has been the subject of active
debate for more than a decade. We do know that one of the
earliest events associated with I/R is a remarkable dysfunction of
the SEC characterized by profound decreases in the steady state
production of eNOS-derived NO.(8,12,13) This decrease in steady
state levels of NO occurs very quickly (within 5 min of reperfu-
sion) and appears to be due to decreased synthesis of NO,
enhanced inactivation of NO by certain ROS or both. Co-incident
with the decrease in NO production is the enhanced production
of ROS such as O2￿− and hydrogen peroxide (H2O2) during the
first few minutes of reperfusion.(4,14–16) The cellular source(s) of
these ROS are not known with certainty but several candidate
enzymes/pathways have been suggested including hepatocyte
xanthine oxidase and/or mitochondrial electron transport as well
as KC- and SEC-associated NADPH oxidase.(4,14,15,17) Interest in
xanthine oxidase has waned over the years in favor of mitochon-
drial sources of ROS and/or KC-associated NADPH oxidase.(7,15,18)
It is well known that certain oxygen-or hemoprotein-derived free
radicals such as O2￿− and ferryl (Fe+4) hemoproteins may interact
with and decompose NO.(19–22) In addition, H2O2 can indirectly
decrease steady state levels of NO via the peroxidase-catalyzed
consumption of NO in different tissues.(23,24) Therefore, I/R-
induced over-production of ROS not only reduces (or eliminates)
the important vasoactive mediator and cytoprotective NO free
radical, but it also induces the rapid oxidation of cellular GSH
creating a more positive redox potential within the liver.(12,16,25,26)
Indeed, a number of different studies, using pharmacologic inter-
ventions or genetic approaches have demonstrated that the protec-
tive effects of certain nonenzymatic or enzymatic antioxidants
administered prior to inducing liver ischemia correlates with
restoration of GSH levels within the tissue.(11,16,26)
Superoxide is the major ROS involved in post ischemic
liver injury. There is a large body of work suggesting that the
major ROS responsible for post-ischemic hepatocellular injury
is O2￿−. A variety of different studies have demonstrated that
adenoviral transfection of the liver with manganese superoxide
dismutase (MnSOD)(14,16) as well as exogenous administration of
long-lived SODs attenuate I/R-induced injury suggesting that O2￿−
per se rather than secondary oxidants is directly or indirectly
responsible for I/R-induced tissue damage (Fig. 2).(3,15,27–29) A
number of cellular sources of O2￿− have been proposed to account
for post-ischemic tissue injury in the absence of an inflammatory
infiltrate. The most likely candidate is KC-associated NADPH
oxidase although SEC NADPH oxidase may play an as yet-to-be
discovered role. This multimeric O2￿−-producing enzymatic
complex has been well-characterized in phagocytic leukocytes
and Kupffer cells. Several studies have determined that KC-
derived NADPH oxidase is critically involved in promoting
post ischemic liver injury.(15,30,31) Exactly how cell-derived O2￿−
promotes liver injury is not known but emerging data suggest
that multiple mechanisms are likely involved. Several studies
had originally suggested that O2￿− dependent lipid peroxidation
represented an important pathway for I/R-induced damage;
however other investigations cautioned that oxidative degradation
Fig. 1. NF κB dependent injurious and protective responses induced by liver ischemia and reperfusion. Ischemia and reperfusion of the liver induc 
es an increase in the production of superoxide and other reactive oxygen species that may directly or indirectly decrease in the bioavailability of NO.
This redox imbalance generates a more oxidative environment within the Kupffer cells, hepatocytes and sinusoidal endothelial cells that is thought
to promote NF κB dependent expression of injurious and protective mediators.
Fig. 2. Effect of SOD2/3 on ischemia and reperfusion induced liver
injury. Mice were treated with the fusion protein SOD2/3 (1,000 U/kg,
iv) or vehicle 15 min prior to being subjected to 90 min of ischemia and
6 h of reperfusion. *: p<0.05 vs vehicle treated mice controls. n≥6
animals per group. Reproduced from (3) with permission.doi: 10.3164/jcbn.11 016FR
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of membrane lipids may, in reality, be a consequence rather than a
cause of I/R-induced liver injury.(32) More recent studies suggest
that O2￿− may directly or indirectly mediate cell and tissue injury
by rapidly interacting with and damaging mitochondrial membrane
proteins leading to the loss of inner membrane potential and ATP
generating capacity.(18,33)
Another mechanism that has been proposed to account for O2￿−
dependent injury to the postischemic liver is through the genera-
tion of even more potent oxidants via its interaction with NO.
This interaction is known to produce the potent cytotoxic oxi-
dizing and nitrating specie peroxynitrite (ONOO−) and its conju-
gate acid peroxynitrous acid (ONOOH).
O2￿− + NO → ONOO− + H+ ←→ ONOOH
Although an attractive hypothesis, the data do not support a
role for this pathway. Indeed, we have found that I/R-induced
liver injury in eNOS-deficient (eNOS−/−) mice or wild type mice
pretreated with the NOS inhibitor N(G)-nitro-L-arginine methyl
ester (L-NAME) exacerbates liver injury suggesting that NO is
protective in nature (Fig. 3).(34) In addition to its direct biochemical
effects, O2￿− may mediate hepatocellular damage indirectly via
the up-regulation (or down-regulation) of certain redox-sensitive
genes known to be important in cell proliferation, apoptosis and
the inflammatory response.(10,35) In addition to the above mentioned
mechanisms, there is good evidence to suggest that I/R-induced
O2￿− production may mediate hepatocellular injury and inflam-
mation by creating a more oxidative environment within the
different cells of the liver thereby activating redox-sensitive
transcription factors such as NF-κB.(4,14,36–39)
Ischemia and reperfusion activates NF-κB: a link between
ROS generation and hepatocellular injury? Studies from several
different laboratories have shown that I/R-induces the rapid up
regulation of several different cytokines (TNF-α, IL-1β, IL-2,
IL-6, IL-8, IL-12), endothelial cell adhesion molecules (ICAM-1,
VCAM-1, E-selectin and mucosal addressin cell adhesion
molecule-1), CXC chemokines (macrophage inflammatory pro-
tein-2, keritinocyte-derived chemokine, and epithelial neutrophil-
activating peptide) as well as nitric oxide synthase-2 (iNOS) and
cyclooxygenase-2 (COX2).(39) The expression of the majority of
these genes is regulated by the transcription factor NF-κB and
thus there is great interest in understanding how the molecular
events associated with I/R-mediated activation of NF-κB and
the subsequent induction and roles of the different cytokines,
chemokines, adhesion molecules and enzymes (Fig. 4). Indeed, it
is now well-appreciated that the expression of TNF-α, IL-1β and
IL-12 are important for mediating post-ischemic liver injury.(15,39,40)
A large body of experimental data suggest O2￿− and/or H2O2
may act as downstream signaling and/or costimulatory molecules
required for the activation of NF-κB.(41) Although an attractive
hypothesis that continues to receive substantial attention in the
literature, there is in fact little data directly demonstrating that
ROS mediate NF-κB activation in vivo.(42,43) It may be that ROS
function to activate NF-κB indirectly by promoting the expression
of certain cytokines and/or mediators (e.g., TNF-α and IL-1β)
which can in turn activate this transcription factor. Indeed, it has
been demonstrated that a major mediator of post-ischemic liver
injury is TNF-α.(15,44) The mechanisms by which TNF-α promotes
hepatocellular injury are not entirely clear but are most likely
multifactorial. Previous studies have suggested that much of the
post-ischemic liver injury may be a result of TNF-α-induced
endothelial cell and hepatocyte apoptosis.(45) It is known that
TNF-α will induce hepatocyte injury via the ROS-dependent
activation of numerous cell signaling pathways resulting in
apoptosis.(38) However, Jaeschke et al. found, using well-defined
histopathological criteria, that virtually all liver injury occurred
by “osmotic necrosis” with very little injury occurring by way of
apoptosis.(45) Nevertheless, it should be remembered that cells
that begin to die by apoptosis may also undergo necrosis if
intracellular ATP is low or absent as would be the case during
ischemia.
It is clear that I/R-induced activation of NF-κB within KCs
and SECs induces an injurious/pro-inflammatory response via the
upregulation of numerous cytokines, enzymes and chemokines
(Fig. 1).(38,39) However, the function of NF-κB in hepatocytes
appears to be more complicated (Fig. 1). Emerging evidence
suggests that NF-κB activation may be to protect a variety of cells
from the injurious effects of certain pro-inflammatory cytokines
such as TNF-α.(38,39) It is well known that pre-treatment of cultured
cells with non-lethal concentrations of TNF-α protects these
cells from a subsequent challenge by lethal amounts of this same
cytokine and that this protective response is dependent upon NF-
κB activation.(38,39) In addition, IKKα has been shown to be
required for embryonic development of skin and limbs whereas
IKKβ appears essential for normal liver development with
massive liver apoptosis, injury and embryonic lethality occurring
in IKKβ-deficient mice.(38,39) Similar effects have been observed
in mice that genetically lack the p65 (relA) component of NF-κB.
Taken together, these studies suggest that NF-κB activation is
essential for normal liver development and that inhibition of
NF-κB nuclear translocation promotes liver injury via massive
apoptosis. Studies by Brenner and coworkers have confirmed that
over-expression of liver IκB-α in mice inhibited NF-κB activation
resulting in massive hepatocyte injury and apoptosis following
partial hepatectomy in these animals.(38,39,46) The mechanisms by
which NF-κB activation protects the liver are only now becoming
understood. It is known that NF-κB activation induces several
“anti-apoptotic” genes including MnSOD, a zinc finger protein
termed A20, cellular inhibitors of apoptosis-2 (c-IAP-2), and
Bcl-2 family members such as A1. Most of these genes (i.e.
MnSOD, A20 and A1) are also known to inhibit NF-κB activation
and thus may control the expression of certain pro-inflammatory
genes (Fig. 1).
Despite the recent body of experimental data demonstrating
that NF-κB may limit hepatocyte injury, there is also an equally
convincing body of data demonstrating that I/R-induced, TNF-α-
mediated liver injury is mediated by NF-κB activation. For
example, it has been shown that much of the post-ischemic liver
injury is abrogated in TNF-α-deficient mice.(47) These are impor-
tant studies as they demonstrate that I/R-induced liver injury is
Fig. 3. Effect of eNOS deficiency on ischemia and reperfusion liver
injury. eNOS deficient (eNOS−/−) or wild type mice were subjected to
45 min of ischemia and 6 h of reperfusion. *: p<0.05 vs sham operated
mice; #: p<0.05 vs time matched wild type muse. n≥6 animals per group.
Data reproduced from (3) with permission. J. Clin. Biochem. Nutr. | January 2011 | vol. 48 | no. 1 | 53
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attenuated in the complete absence of NF-κB activation ie in the
absence of both the injurious/inflammatory and the protective
responses. It may be that the balance between injurious vs protec-
tive genes upregulated during I/R as well as the cellular location
of NF-κB activation dictates whether NF-κB activation will
promote injury or protection. A more direct approach to the role of
hepatocyte NF-κB in the pathophysiology of post-ischemic tissue
injury has been provided by investigators who showed that I/R-
induced injury was attenuated in mice with hepatocyte-specific
ablation of IKKβ.(48) They found that the protective effect was
associated with decreased expression of hepatocyte-derived
TNF-α.(48) In apparent contradiction to these results, these same
investigators reported that I/R-induced liver injury in mice with a
hepatocyte-specific deletion of IKKγ (NEMO) was dramatically
increased compared to wild type mice suggesting a protective
effect of hepatocyte NF-κB.(49) In an attempt to reconcile these
seemingly contradictory results, the authors suggested that
hepatocyte-specific deletion of IKKβ may possess some residual
NF-κB activity whereas IKKγ (NEMO)-deficient hepatocytes
have no detectable NF-κB activity and thus no protective response
to limit liver damage. Taken together, these data suggest that
further work is needed to define the role of hepatocyte NF-κB.
Role of Leukocytes in I/R Injury
The early phase of I/R injury is a PMN-independent process in
which KCs are activated, ROS are generated by these resident
phagocytes and by dysfunctional mitochondria in KCs, SECs
and hepatocytes and proinflammatory cytokines (TNF-α, IL-12,
IL-1β) are synthesized. This initial response induces the upregula-
tion of additional inflammatory mediators including activated
complement factors (e.g., C5a), platelet activating factor and
different CXC chemokines, such as interleukin-8 (IL-8), macro-
phage inflammatory protein-2 (MIP-2), keratinocyte-derived
chemokine, and cytokine-induced neutrophil chemoattractant
(CINC-1).(7) These inflammatory mediators promote the enhanced
expression of CD11b/CD18 which prime PMNs and promote
their extravasation from the sinusoids and post-sinusoidal venules
into the tissue thereby initiating the late or subacute phase of post-
ischemic tissue injury. This inflammatory response is character-
ized by the activation of PMNs resulting in the production of
large amounts of ROS and release of a variety of different
proteases (gelatinase, collagenase). The net result of this acute
inflammatory response is oxidant-mediated mitochondrial dys-
function as well as degradation of the interstitial matrix and
damage to the parenchymal cells.(7) In addition, TLR4-mediated
production of cytokines and inflammatory mediators may represent
an additional important pathway for the amplification of the
inflammatory response. Although it is well-recognized that PMNs
play an important role in the pathophysiology of Iiver I/R injury,
other leukocytes may also be involved in this innate immune
response. For example, it has been reported that CD4+ T-cells
Fig. 4. Classical and Alternative Pathways for ischemia and reperfusion induced activation of NF κB. Derived from (39).doi: 10.3164/jcbn.11 016FR
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play an important role in recruiting PMNs into the post-ischemic
liver and that CD4+ T-cell-deficiency remarkably attenuated
both PMN infiltration and tissue injury following I/R.(50) However,
more recent studies have found that CD4+ T-cell-deficient mice
responded to liver I/R with an exacerbation in liver injury despite
the fact that these mice displayed fewer PMNs infiltrating the
post-ischemic liver.(6) The mechanisms responsible for these
seemingly contradictory results are not clear at the present time
but may relate to the suppressive or regulatory nature of the
infiltrating CD4+ T-cells in the later study.
Suppression of I/R Induced Liver Damage by Endogenous
or Exogenous Nitric Oxide
It is becoming increasingly appreciated that I/R results in rapid
endothelial dysfunction in a number of different tissues that is
characterized by a marked decrease in steady-state production of
endothelial cell-derived NO.(8,12,51,52) The decrease in NO bio-
availability occurs within the first few minutes following reperfu-
sion and appears to be due to decreased synthesis of NO, enhanced
inactivation of NO by O2￿− (or other ROS) or both. Because endo-
genous NO is known to interact with and rapidly decompose
certain ROS such as O2￿−, HO￿, and ferryl hemoproteins, decreased
steady state production of NO would in all likelihood increase the
redox potential of hepatocytes, KCs and/or SECs in favor of a
more oxidative environment.(26,52) Indeed, we have demonstrated
that many of the pathophysiological characteristics induced by
I/R (i.e. oxidative stress, leukocyte adhesion, enhanced vascular
permeability) may be recapitulated in normal tissue by administra-
tion of certain NOS inhibitors(12,51,52) suggesting that eNOS-
derived NO may act as an endogenous anti-inflammatory mediator
in the microcirculation.
The use of certain NOS inhibitors to evaluate the role of NO in
vivo has proven problematic. It is known for example that L-
NAME and L-NMMA are nonspecific inhibitors of both eNOS
and iNOS as well as potent vasoconstrictors in vivo.(53) Thus, the
non-selective nature of these NOS inhibitors coupled to the fact
that their exacerbatory effects may be due to their vasoconstrictor
effects in a model of hypoperfusion makes their usefulness less
than ideal to probe the role for NO in liver I/R. The potentially
protective role of endogenous NO in liver I/R injury is supported
by studies demonstrating enhanced hepatocellular injury in post-
ischemic animals rendered deficient in eNOS (Fig. 3).(34,54) In
addition, investigators have demonstrated that NO donors or
over-expression of liver eNOS protects mice from liver I/R-
induced injury.(55–57) Although eNOS has been shown by several
groups of investigators to play a critical protective role in liver I/R
injury, the role of iNOS is less clear. Studies from our laboratory
suggest that I/R-induced liver injury is enhanced in iNOS-
deficient mice however interpretation is complicated by the fact
that we could not demonstrate upregulation of iNOS message in
post-ischemic livers of wild type mice suggesting that the source
of iNOS is not in the liver (e.g., in the intestine) or that a small
population of cells such as KCs or SECs upregulate iNOS which
we are unable to detect in whole liver preparations.(58,59)
The mechanisms by which endogenous NO protects the liver
against the injurious effects of I/R are now beginning to be defined
(Fig. 5). NO is known to interact with and decompose O2￿− or other
reactive radicals or oxidants thereby limiting the formation of O2￿−-
derived oxidants and preventing the downstream oxidant-induced
signaling pathways.(25) If this antioxidant/free radical scavenging
activity of NO is a major protective mechanism, then one would
predict that administration of a long lived SOD such as the fusion
protein SOD2/3 to eNOS-deficient mice would attenuate I/R-
induced injury to the liver. In fact, we found that although
SOD2/3 markedly attenuates post-ischemic injury in wild type
mice, it does not attenuate liver injury in eNOS-deficient
animals.(34) These data suggested that the protective effect of
SOD2/3 in wild type mice is due to its ability to increase the
bioavailability of NO by preventing the O2￿− mediated inactivation
of NO. We then return to the question: How does NO limit I/R-
induced tissue damage? There is data suggesting that NO inhibits
NF-κB activation at different levels. For example, DeCaterina
and coworkers provide evidence that NO enhances the denovo
synthesis and/or stabilization of the natural inhibitor IκB-α.(60) In
addition, NO-mediated S-nitrosation of a specific cysteine on the
p50 and/or p65 subunits of NF-κB results in inhibition of binding
of this heterodimer to it consensus sequences upstream of the
different pro-inflammatory genes.(61–63) Another possible mecha-
nism may be that NO-dependent activation of soluble guanylyl
cyclase (sGC) with the subsequent production of the vasorelaxant
cGMP may protect against reperfusion injury by enhancing blood
flow thereby limiting the degree of ischemia to the liver. It has also
been proposed that NO-mediated activation of protein kinase G
via the sGC/cGMP pathway opens mitochondrial KATP channels
thereby reducing calcium accumulation within the mitochondria
and preventing the loss of cytochrome c from the mitochondrial
intermembranal space.(9) Alternatively or in addition to, NO may
reversibly inhibit mitochondrial respiration via interaction with
complex I and/or cytochrome c oxidase. This would inhibit
apoptosis, maintain small but significant amounts of oxygen
during ischemia and allow for a more controlled resumption of
respiration following reperfusion.(9) Similar observations have been
made with NO-dependent S-nitrosation of caspase-3 resulting in
inactivation of this enzyme and inhibition of apoposis.(9) This
would minimize free radical-mediated damage to the mitochon-
drial membrane and preserve cellular function. NO may attenuate
the later stages of post-ischemic tissue damage by inhibiting
platelet/leukocyte-endothelial cell interactions.(12,51,64)
There is ample evidence demonstrating that eNOS-derived NO
as well as exogenous NO-releasing compounds attenuate I/R-
induced liver injury.(13,34,55,57,65) More recent studies demonstrate
that animals and humans are capable of producing substantial
quantities of NO via eNOS-independent pathways that utilize
nitrogen oxides that are produced from the decomposition of NO
Fig. 5. Proposed cytoprotective mechanisms for eNOS  or nitrite (NO2−) 
derived nitric oxide (NO). NO derived from eNOS or NO2− may protect
tissue subjected to ischemia and reperfusion by: a) Inactivation of
caspase 3 via the NO dependent S nitrosation of the protein; b) cGMP/
protein kinase G (cGMP/PKG) mediated opening of mitochondrial ATP 
dependent potassium channels (KATP) which reduces the loss of cyto 
chrome C, decreases calcium accumulation within the mitochondria,
prevent the opening of the mitochondrial permeablility transition
(MPT) pore and decrease apoptosis; c) Inhibition of mitochondrial
electron transport via the direct or indirect (S nitrosation) inhibition
of Complex I (and possible Complex IV) resulting in decreased reactive
oxygen specie (ROS) generation, reduced cytochrome C release and
decreased apoptosis. J. Clin. Biochem. Nutr. | January 2011 | vol. 48 | no. 1 | 55
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or are ingested in the diet. Like any important signaling molecule,
the generation and lifetime of NO is very short-lived in vivo.
Indeed, NO may be rapidly inactivated by a variety of different
mechanisms.(66) A physiologically-relevant set of pathways for
the inactivation of NO are mediated by metal-catalyzed oxida-
tion reactions. The copper-containing protein ceruloplasmin has
been shown to rapidly oxidize NO to NO2− under physiological
conditions. In addition to ceruloplasmin, ferrous dioxygenated
hemoglobin (Hb-Fe+2O2; oxyhemoglobin) or myoblobin rapidly
decomposes NO to yield nitrate.
Historically, it has been assumed that blood and tissue nitrate
and nitrite simply reflect inert endproducts of NO metabolism
and food contaminants. However, it is now recognized that these
oxidized metabolites of nitrogen can be metabolized in vivo to
regenerate NO (Fig. 6).(66) Because the rate of NO generation from
nitrite is linearly dependent on reductions in tissue pO2 and pH,
nitrite may be metabolized to NO in ischemic tissue (via deoxyHb
or Mb) and exert NO-dependent protective effects site-specifically.
Indeed, the tissue-specific reduction of nitrite to generate cyto-
protective NO has important clinical significance in that treatment
of different ischemic disorders with nitrite would reduce the
untoward cardiovascular effects of systemic delivery of inhaled
NO or intravenous administration of S-nitrosothiols. A growing
number of studies demonstrate that nitrite is cytoprotective in
different models of tissue I/R including the liver, heart, kidney
and brain (reviewed in Ref. 9). The clinical usefulness of nitrite is
currently being investigated as a potential therapeutic agent to
treat ischemic disorders.
Concluding Remarks
There is now overwhelming evidence supporting the concept
that I/R-induced tissue damage is associated with the O2￿−-
dependent decrease in steady-state levels of NO. Furthermore,
accumulating evidence suggests that eNOS-dependent as well as
eNOS-independent generation of NO acts to limit post-ischemic
tissue injury. The mechanisms by which this nitrogen oxide
protects the post-ischemic liver remain to be defined and are the
subject of active investigation. Therapeutic uses of NO or nitrite
are currently underway in several different laboratories to treat a
variety of ischemic disorders.
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